SIRT1 and acute myeloid leukemia: Chidamide, a novel benzamide histone deacetylase inhibitor, enhances the AML cell cytotoxicity of the chemotherapy drugs Ara-C and sorafenib by upregulating histone H3 lysine 9 trimethylation (H3K9me3) and downregulating autophagy by inhibiting SIRT1 expression [214].